Senseonics Holdings, Inc. reported second quarter 2026 financial results on August 6, 2026, revealing a 120% year-over-year revenue surge to $14.5 million. The medical technology company, focused on implantable continuous glucose monitoring (CGM) systems, achieved this growth through robust U.S. commercial momentum and expanded gross margins. This performance validates the company’s strategy of bringing U.S. and European commercial operations in-house, with U.S. revenue growing more than 150% year-over-year to $12.6 million.

The company raised its full-year 2026 global net revenue guidance to a range of $62 million to $66 million, up from the previous guidance of $60 million to $64 million, representing year-over-year growth of 76% to 87%. Additionally, Senseonics increased its full-year gross margin guidance to 58% to 61% from the prior range of 55% to 58%. These adjustments reflect the ongoing roll-out of Eversense 365 outside the United States and improved productivity across health care provider channels.

Financial Performance Details

Total revenue for the second quarter of 2026 was $14.5 million, comprising $12.6 million from U.S. operations and $1.9 million from international markets. International revenue increased by approximately 12% compared to $1.7 million in the prior year period, with the company noting that timing dynamics related to tender updates in Europe are expected to normalize in the third and fourth quarters.

Operating expenses increased significantly due to commercial integration efforts. Selling, general and administrative expenses rose to $32.9 million from $9.7 million in the prior year period, primarily related to the transition from Ascensia in Europe. Research and development expenses were $11.6 million, compared to $7.7 million in the second quarter of 2025, reflecting clinical activities for the Gemini program and development of Freedom. Consequently, the net loss widened to $36.7 million, or $0.63 per share, from $14.5 million, or $0.36 per share, in the same period last year.

Balance Sheet and Liquidity

As of June 30, 2026, cash, restricted cash, and cash equivalents totaled $143.0 million. Outstanding indebtedness, including accrued interest, stood at $55.5 million. This strengthened balance sheet reflects more than $100 million raised during the second quarter, consisting of approximately $90 million in equity proceeds and an expanded credit facility with Hercules Capital of up to $140 million.

What the Numbers Show

The divergence between top-line growth and bottom-line results highlights the transitional nature of Senseonics’ current phase. While revenue surged 120% and gross margins expanded by 12 percentage points to 59%, operating losses widened significantly due to a 238% increase in selling, general and administrative expenses. This indicates that the immediate financial benefit of bringing commercial operations in-house is currently offset by higher fixed costs associated with building internal sales and marketing capabilities in the U.S. and Europe. However, the raised full-year guidance suggests management expects these investments to yield scalable returns as European tender timing normalizes and Eon Care, which has scaled past 90 nurses, continues to expand.

Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, stated that the quarter marked the strongest in the company’s history, achieving record revenue and expanded margins while integrating European commercial operations. Brian Hansen, Chief Commercial Officer, noted continued uptake of Eversense 365 in combination with the twiist Automated Insulin Delivery system, reinforcing the company’s position in the diabetes management market.

Senseonics Holdings, Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The medical technology company, focused on implantable Continuous Glucose Monitoring (CGM) Systems, scheduled the announcement to provide updates on its operational performance. The disclosure is critical for investors tracking the progress of its Eversense 365 and Eversense E3 CGM systems.

Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. Eastern Time on the same day. The call will be concurrently webcast, with the link available on Senseonics Holdings, Inc.'s website under the "Investor Relations" section. An archive of the webcast will be retained for future reference.

To participate in the conference call, investors can dial 1-833-354-6854 (US/Canada) or 1-785-838-9343 (International) using the passcode SENSQ2. Participants are advised to dial in approximately ten to five minutes prior to the start time.

Event Details

Senseonics Holdings, Inc. specializes in long-term implantable glucose management technology. Its CGM systems feature a sensor inserted under the skin that communicates with a smart transmitter, sending glucose data every five minutes to a mobile app.